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Abstract
Combinations of healthcare claims data with additional datasets provide large and rich sources of information. The dimen‑
sionality and complexity of these combined datasets can be challenging to handle with standard statistical analyses. How‑
ever, recent developments in artificial intelligence (AI) have led to algorithms and systems that are able to learn and extract 
complex patterns from such data. AI has already been applied successfully to such combined datasets, with applications such 
as improving the insurance claim processing pipeline and reducing estimation biases in retrospective studies. Nevertheless, 
there is still the potential to do much more. The identification of complex patterns within high dimensional datasets may 
find new predictors for early onset of diseases or lead to a more proactive offering of personalized preventive services. While 
there are potential risks and challenges associated with the use of AI, these are not insurmountable. As with the introduction 
of any innovation, it will be necessary to be thoughtful and responsible as we increasingly apply AI methods in healthcare.
Key Points for Decision Makers 
The use of artificial intelligence (AI) with claims data 
has the ability to identify and reduce common biases in 
healthcare, such as doctor and omitted variable biases.
The ability of AI to detect intricate patterns in claims 
data pooled with other sources can lead to better care 
(e.g., detection of underdiagnosed diseases) and insur‑
ance coverage processes.
Patient confidentiality, methodological transparency, and 
potential discrimination are important issues to consider 
when using AI with claims data.
1 Introduction
Healthcare claims data provide structured information on 
patient interactions with the healthcare system, such as treat‑
ments given, providers used, billed amounts, and prescrip‑
tions filled. They consist of the billing codes that healthcare 
providers, such as physicians and hospitals, submit for pay‑
ment by commercial and government health plans. Since 
they are collected regularly for administrative purposes, 
healthcare claims provide a relatively inexpensive source 
of information, over long time periods, for large numbers of 
patients. Moreover, as our payment structures change and 
patients ask more of their providers, the volume of available 
claims data is likely to increase rapidly.
The large sample sizes can be useful for studying rare 
conditions and the longitudinal dimension of the data allows 
researchers to examine treatment adherence and effects over 
time. However, healthcare claims typically provide only lim‑
ited information on clinical severity, patients’ health status, 
and other variables of interest [1]. This can be ameliorated 
by supplementing claims data via linkages with other data 
sources, such as census data to account for neighborhood 
income or electronic medical records (EMRs) to obtain more 
clinical information [2].1 These linkages open the door for a 
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1 Another, more recent, source of information that could possibly be 
combined with claims data is ‘telehealth’ technology. This technol‑
ogy has made it possible for individuals to use their computers and 
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number of research possibilities, as relevant healthcare data 
can come in a variety of unstructured formats, such as text, 
pictures, audio, or video files.2
While linked datasets permit a more comprehensive 
comparative analysis of alternative health technologies and 
interventions [4], incorporating the additional dimensional‑
ity and complexity of the data into the analysis can present 
challenges for standard statistical analysis [5]. In particu‑
lar, explicit functional relationships in novel combinations 
of data may be unknown ex ante. Recent developments in 
artificial intelligence (AI) research have led to computer 
algorithms and systems with the ability to learn and extract 
complex patterns from raw data [6]. For example, machine 
learning algorithms, such as random forests and deep convo‑
lutional neural networks, often detect intricate relationships 
between input and output variables to improve out‑of‑sample 
predictions. Natural language processing algorithms can be 
used to parse and interpret written text. AI algorithms have 
been applied successfully in many domains of business, gov‑
ernment, and science [7].
There are important differences in emphasis between 
standard statistics and AI algorithms. Standard statistics 
emphasize our understanding of underlying mechanisms 
(i.e., fitting a specific model and hypothesis testing). While 
AI algorithms can often detect unforeseen relationships and 
complicated nonlinear interactions within the data, their 
emphasis is typically on prediction accuracy (e.g., identify‑
ing the best treatment or course of action) [5].
Multiple approaches have been developed to palliate 
concerns about the interpretability of AI algorithms. For 
example, recent research has developed measures of the 
importance of specific covariates based on how much each 
contributes to the prediction accuracy of the model(s) [8, 9].3 
Like standard statistical methods, these importance meas‑
ures can be biased based on the data used or the variables 
included in the model. However, they do allow researchers 
to tie predictive AI models back to intuitive relationships 
and existing knowledge.4 Another approach is to develop 
methods that ally the flexibility of AI and the interpretability 
of simpler models, such as optimal classification tree meth‑
ods.5 These approaches are particularly valuable in health‑
care settings, in which it can be particularly important to 
understand the decision process behind a decision, such as 
a diagnosis or treatment.
In this paper we discuss some recent and potential 
applications of AI to healthcare claims data.6 AI has the 
potential to improve the detection of diseases and treat‑
ment adverse effects, identify and reduce diagnostic errors 
or personal biases, and improve the monitoring of insur‑
ance costs and fraud. However, this potential is associated 
with risks and challenges. Patient confidentiality, meth‑
odological transparency, and potential discrimination are 
important issues to consider when using AI with claims 
data.
2  Making the Most of Healthcare Claims 
Data
‘Artificial intelligence,’ broadly defined, is the ability for 
machines to perform tasks characteristic of human intelli‑
gence. In this paper we focus on machine learning algo‑
rithms, which are a subset of AI. Rather than researchers 
assuming explicit functional relationships between vari‑
ables, machine learning algorithms are designed to learn 
relationships from the data. These learned relationships can 
be exploited to improve data analytics relying on claims 
data in numerous ways. Some examples are presented in 
this section.
3 These measures permute the values of the covariate, breaking the 
relationship between the covariate and outcome, and calculate the 
corresponding increase in the prediction error. A covariate is consid‑
ered more important the more its permutation increases prediction 
errors, since this implies the model relied on the covariate for predic‑
tion.
4 Questions relating to statistical significance are also often 
approached differently in the AI world. AI algorithms are typically 
5 Researchers continue to improve the predictive ability of machine 
learning algorithms. Among these algorithms, decision trees are often 
preferred due to their interpretability. Optimal classification trees are 
an example of recent research that improves predictions while main‑
taining interpretability [10].
6 Our discussion in this paper is not intended to be exhaustive as the 
set of potential applications is likely quite large. For example, while 
we do not discuss it in depth here, AI can possibly help alleviate 
shortages of clinical staff by taking on some of their responsibilities 
(e.g., the diagnostic responsibilities of neurologists). In this way, AI 
may increase the access to healthcare, particularly in remote regions 
where it may be difficult to attract practitioners.
Footnote 1 (continued)
phones to access healthcare services remotely. For example, patients 
can potentially use their phones to upload their food logs, medica‑
tions, or dosing for review by a doctor or nurse [3].
2 Examples include doctors’ notes, computed tomography (CT) 
scans, and video recordings of clinical encounters.
used with very large datasets, in which it is often possible to find 
statistical significance despite a variable being associated with very 
small differences in the outcome variable. In certain applications it 
may therefore be more useful to determine variables’ economic or 
clinical significance rather than focusing solely on their statistical sig‑
nificance.
Footnote 4 (continued)
Opportunities and Challenges of Combining AI with Healthcare Claims Data
2.1  Pooling Knowledge to Provide Better Care
A significant advantage of AI over standard statistical analy‑
sis is its ability to examine large multidimensional data with 
many variables. A statistician may easily be overwhelmed 
by a large number of potentially usable variables. AI algo‑
rithms, in contrast, are often able to identify which variables 
are important and detect the optimal combination of these 
variables for the task at hand.
By combining claims data with other information sources, 
such as patients’ laboratory results and EMRs, the knowl‑
edge and experience of a wide range of medical practitioners 
can be pooled together to detect complex patterns indicative 
of certain illnesses. The identification of these patterns can 
improve the early detection of diseases and the detection 
of underdiagnosed or rare diseases, provide more accurate 
diagnoses, or lead to a more proactive offering of personal‑
ized preventive services.
In the case of conditions that are underdiagnosed, for 
example, a sample of patient claims data (combined with 
laboratory values, specialist visits, and physician notes) can 
be analyzed by physicians to determine which of the patients 
should have been diagnosed and at what point in time. This 
process can then be used to train algorithms to detect other 
instances that should be flagged and identify early markers 
and indicators of future disease onset. For example, recent 
research has used AI to predict type 2 diabetes mellitus using 
claims data [11]. More generally, there have been a number 
of applications using AI with other types of data (e.g., CT 
scans, or genome sequencing in precision medicine) to sup‑
port diagnoses, either through the prediction of disease onset 
or the identification of drug‑resistant strains of disease (e.g., 
drug‑resistant tuberculosis [12]).
Another promising application of AI is the detection of 
treatment adverse effects. Adverse effects are typically hard 
to discover in standard human trials because of relatively 
small sample sizes. Large claims data may help discover 
these adverse effects, in particular when combined with the 
pattern recognition power of AI. Recent research has used 
machine learning algorithms to detect adverse drug reactions 
using EMR data [13]. Healthcare administrative data can be 
linked with EMR data to add more clinical information [2], 
and may improve detection. More generally, as discussed 
by Dadson et al. [14], AI has been used to detect drug–drug 
interactions based on the text in government and scientific 
reporting systems and may be used with genomic data to 
determine genetic factors associated with particular adverse 
effects.
AI has also been used broadly to systematically learn 
from past experience. Examining patterns in pooled data 
can improve the monitoring of services, such as hospital 
readmissions or diseases contracted on site. For example, 
machine learning analysis on patients’ electronic health 
records, demographics, medical histories, admission and 
hospitalization histories, and likely exposure to the Clostrid-
ium difficile bacterium was shown to increase the accuracy 
in predicting the risk of hospital infections [15].
2.2  Identifying and Reducing the Effects of Biases
AI also has the potential to identify and reduce the effects 
of common biases in healthcare, such as doctor biases and 
omitted variable bias.
2.2.1  Doctor Bias
Doctors may exhibit biases in their propensities to prescribe 
particular drugs. These biases may result from the limited 
time doctors have to make a diagnosis, the information doc‑
tors are exposed to (e.g., limited samples, medical press, or 
patient history), doctors’ own, potentially self‑reinforcing, 
experience (e.g., repeated diagnoses), or they may result 
from specific cognitive biases or personality traits (e.g., 
aversion to risk or ambiguity) or forecasting biases (e.g., 
over‑confidence or belief in the law of small numbers) [16].
As described earlier, AI used on claims data pooled with 
information from other sources can provide support for bet‑
ter care. Taking advantage of more knowledge and varied 
experience can reduce doctors’ biases in decision‑making. 
Doctors could be provided with a statistical diagnosis tool 
using models calibrated with data. For example, AI algo‑
rithms could scan patient histories, data, and relevant lit‑
erature as a doctor is entering observations and notify the 
doctor of potentially useful information. In some settings, 
the diagnostic tool could also incorporate prior expert 
knowledge and decision‑making into a predictive AI algo‑
rithm [17]. Although this tool would be limited to the extent 
that the relevant data can be encoded and made machine‑
readable, it could complement the doctor’s judgement with 
unbiased information [18].
2.2.2  Omitted Variable Bias
Claims data often contain information about specific treat‑
ments not available via randomized trials [19]. Using this 
information, algorithms can identify covariates correlated to 
both outcomes and treatment that previous researchers did 
not realize were important. This can reduce bias by ensur‑
ing no pertinent variables are omitted from the statistical 
analysis. In addition, AI prediction tools also feature a vari‑
ety of methods to avoid overfitting and exclude superfluous 
variables.
Despite its richness, there is some potentially relevant 
information that may be missing or limited in claims data, 
even after pooling it with other sources, which can lead to 
omitted variable bias. The lack of lifestyle characteristics 
 D. Thesmar et al.
information is often cited as a main limitation of claims data 
[20]. Information on how the recommended treatment was 
followed by the patient or the ‘quality of care’ may also be 
missing. The ability of AI to find complex patterns in the 
data can potentially approximate this missing information 
via combinations of the variables that are available. This 
can improve the matching of treated and untreated patients, 
which in turn helps correct for treatment selection biases 
in retrospective studies of treatment efficacy or safety [21].
For example, it is notoriously difficult to compare the 
effect of different treatments based on retrospective stud‑
ies. The decision to prescribe one treatment over another is 
generally informed by a doctor’s evaluation, and the factors 
that affect that evaluation, such as the patient’s disease sever‑
ity, other co‑morbidities, and history of compliance, may be 
unobservable to the researcher. If, say, one treatment tends 
to be used for more severe cases, comparing its efficacy (or 
safety) against another treatment without controlling for this 
tendency will bias the results in favor of the treatment that is 
typically used for easier cases.
Propensity score matching is one statistical technique 
used to limit this bias. The method essentially relies on a 
two‑step process in which the probability that the doctor 
will prescribe a given treatment is estimated in the first step 
and then used in second step to account for differences in 
patient characteristics that affected the prescribing decision. 
An intuitive way to think about the first step is that it is an 
attempt to mimic (or predict) the doctor’s prescribing deci‑
sion based on patient information. The better the predic‑
tion in the first step of the procedure, the smaller the bias 
in the overall comparison of treatments. Some researchers 
have advocated the use of a ‘chain of proxies’ often found in 
claims data to improve prediction (e.g., old age may serve as 
a proxy for co‑morbidity or cognitive decline) [22]. Through 
the detection of intricate patterns amongst these proxies, 
AI methods can improve predictions even further. Recent 
research demonstrates that significant bias can remain in 
many claims data applications after using conventional 
methods and that the use of AI can significantly reduce, and 
essentially eliminate, such biases [21, 23, 24].
2.3  Improving Insurance Coverage Processes 
and Fairness
AI has had an influence on each step of the processing 
pipeline for insurance coverage: claim submission, claim 
adjudication, and fraud monitoring. Its influence is likely to 
continue well into the future.
An efficient and accurate intake process for claims sub‑
missions can reduce burdens on patients and the entire 
medical system. For example, AI image recognition can 
be used to facilitate the process of submitting and coding 
claims. One insurance company has trialed a procedure 
to automate claim approvals. Patients electronically sub‑
mit photos of their hospital bills and, within moments, 
receive notification of receipt, approval, and credit to their 
account [25]. The cost savings associated with this auto‑
mation process may allow insurance companies to scale 
up and provide more coverage. Some insurance companies 
have developed algorithms that recommend and incentiv‑
ize healthy habits and behaviors to policyholders, such as 
exercise and nutrition strategies [26]. If successful, these 
may avoid claims submissions for preventable illnesses 
altogether.
Claim adjudication involves checking coverage, limits, 
contracts with providers, pharmacies, appropriate diagno‑
sis, and procedure coding. Complex and suspicious claims 
trigger secondary, usually manual, processing steps. AI can 
save time via the efficient processing of normal claims (e.g., 
through increased automation in the settlement of claims 
based on their complexity and known patient history) [27]. 
In addition, AI can be used for early detection of abnormal 
price patterns among healthcare providers. This may help 
insurance companies monitor their costs and understand 
whether price increases reflect actual quality improvements.
Increasing the accuracy of triaging claims through AI 
can reduce losses due to fraud (e.g., a provider billing for 
services that were not actually provided or the provision 
of unnecessary medical services to generate insurance pay‑
ments). While the share of actual fraudulent claims is gener‑
ally very low [28], these can add up to very significant dollar 
amounts. Just counting savings to Medicare, the Health Care 
Fraud Unit of the US Department of Justice’s Criminal Divi‑
sion recovered and transferred billions of dollars in the 2017 
fiscal year [29]. Several data mining efforts have been under‑
taken with increasing levels of sophistication to improve 
fraud detection [30]. A Google Patent search for “healthcare 
machine learning fraud detection” reveals over 7700 results 
[31]. The general challenge is to limit false positives, which 
can lead to losses in reputation of targeted firms as well 
as enforcement efforts that are channeled inappropriately, 
while increasing the proportion of fraud detected. The rules 
to detect individual fraud are now relatively simple to imple‑
ment. Recently, more complex network fraud pattern recog‑
nition algorithms have been developed with the potential to 
significantly reduce the costs for insurers [32].
3  Risks and Challenges
While there is great potential for AI applications with claims 
data, this potential is associated with risks and challenges. 
Issues related to confidentiality, clarity of scope, appropri‑
ate methodology, and transparency of results need to be 
addressed.
Opportunities and Challenges of Combining AI with Healthcare Claims Data
3.1  Data Provenance: Confidentiality and Quality
Most ethical problems related to confidentiality can be 
dealt with by anonymizing the data. In the past, removing 
social security numbers, phone numbers, names, and most 
date of birth information was sufficient to anonymize data. 
However, the recent emergence of third‑party datasets (e.g., 
social media and cell phone tower access records) has pro‑
vided additional avenues to triangulate datapoints and iden‑
tify individuals within the data [33]. This creates additional 
challenges and a potential need for better de‑identification 
techniques that ensure that shared information cannot be 
used to approximate personal information even when com‑
bined with pattern detection techniques.
3.2  Data Use: Interpretation of Methodological 
Approaches
As is the case with standard statistical methods, AI algo‑
rithms built on biased data will lead to biased predictions. 
Supervised machine learning algorithms, for instance, learn 
relationships between outcome and predictor variables after 
being trained on a set of examples for which the true out‑
come is known. Algorithms will have trouble classifying 
new examples that are very different to what they have seen 
before. In machine learning this problem is referred to as 
“hasty generalization” [34]. While this problem is not unique 
to AI, the rapid speed at which individuals are now able to 
analyze large datasets has raised concerns that some believe 
the need for evidence of causal relationships is unnecessary, 
large databases by themselves are enough, and that the num‑
bers will speak for themselves [35]. While complex correla‑
tion patterns are useful for making predictions, they may be 
of limited use for explaining why certain events occur [36].7 
The importance measures [8, 9] and highly interpretable AI 
models [10] discussed earlier can be useful in this regard.
Using AI or any statistical tool requires careful consid‑
eration of both the underlying data and the results. There 
are inherent biases in most claims databases due to sample 
selection (e.g., the characteristics of the insured population 
and varying standards of care), such that results may not 
be generalizable to other population groups. For instance, 
evaluating the effect of a drug that requires a very demand‑
ing treatment on a subpopulation with a high adherence rate 
may overestimate the effectiveness of the drug on the gen‑
eral population. In addition, the decisions made in real‑life 
applications based on an algorithm’s results can have lasting 
effects (e.g., if an individual is incorrectly declined insur‑
ance because their profile shares some characteristics with 
at‑risk groups) [39].
Supplementing claims data with information from other 
sources may limit the potential bias from unobserved vari‑
ables. As discussed earlier, particularly rich data may also 
be used to triangulate and proxy for information that is still 
missing. However, rather than relying on technology to solve 
potential issues ex post, recent research has investigated 
whether technology can help gather more exhaustive, rich, 
and less biased datasets ex ante. For example, the blockchain 
technology associated with bitcoin is being considered as 
a potential solution to securely store healthcare data. Indi‑
viduals would have ownership over their own personal data 
and would potentially receive financial incentives to make 
it widely available. Blockchain technology could also help 
document the provenance, veracity, and selection of the data 
used in studies. This could greatly reduce the widespread 
difficulty in replicating published medical research. Relat‑
edly, this documentation could reduce the ability to cherry‑
pick results [40].
Table 1  Examples of benefits and challenges
A. Benefits
Pooling knowledge
 Early detection of disease and readmission
 Identification of underdiagnosed/rare diseases
 Personalized preventive services
 Monitoring of adverse effects
Reducing biases
 Doctor biases
 Omitted variable biases
Improving the insurance pipeline
 Claim submissions
 Claim adjudication
 Fraud monitoring
B. Challenges
Data provenance
 Confidentiality
 Need for exhaustive, unbiased data
Interpretation of methodological approaches
 Hasty generalization
 Lasting effects of real‑life decisions
Discrimination
 Premiums based on personal traits
 Reproduction of biases
7 In addition, for a new machine learning algorithm called estimating 
the maximum (EMX), researchers have found situations in which it 
is impossible to prove mathematically whether or not the algorithm 
could actually solve a particular problem. These findings suggest that 
some level of caution should be exercised when using new AI meth‑
ods [37, 38].
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3.3  Usage: Prevention of an Adverse Welfare Impact 
from Discrimination
Just as AI algorithms can help detect a disease in its earli‑
est stage, they can also help predict future health costs and 
therefore be used, in theory, to adjust insurance premiums 
based on combinations of personal characteristics. If an 
insurer can predict illness reliably, competition could lead 
to lower premiums for predictably healthier individuals 
and higher premiums for predictably sicker ones, even if 
the characteristics used for prediction are beyond an indi‑
vidual’s control.
Even if such a process could be appropriately imple‑
mented, it may be economically inefficient. An individual 
who is uncertain about their future sickness would want to 
smooth their future income across possible states of nature 
(e.g., sick vs. not sick). The individual would want insur‑
ance, but if the insurance company has reliable forecasting 
technology, competition could undermine that person’s abil‑
ity to obtain insurance, leaving the individual worse off.8
The extent to which such insurer strategies are already 
used and how much should be prohibited by law is often the 
subject of debate, particularly since similar issues appear 
in other industries. For example, research on credit access 
has examined the use of variables correlated with race and 
gender when evaluating loan requests and the potential bias 
against certain groups [42, 43].
At issue in these cases is not the methodology itself but 
rather its use. Let us assume, for example, that loans are 
evaluated by a group including individuals with biases (e.g., 
against immigrant or older loan applicants). If an algorithm 
is trained to mimic the decisions of these individuals (i.e., 
predict the loan approval decision) it will implicitly repro‑
duce these biases. However, if the algorithm is trained to 
predict the future return of the investments made (i.e., the 
loans), the algorithm may show that unbiased decisions lead 
to better outcomes and may therefore provide better recom‑
mendations. In that case the AI algorithms might, for exam‑
ple, better align loan decisions with firms’ long‑term profit 
interests while reducing biases [44].
AI methodologies are therefore not inherently good or 
bad, biased or clean. They are what we make of them. Inter‑
estingly, AI and claims data can be used to analyze the scope 
of the potential insurance discrimination problem, by exam‑
ining the insurance premium distribution and identifying the 
groups that benefit for different scenarios of harmonization 
versus tailoring of premium rates.
4  Conclusion
Linkages of claims data with additional datasets provide rich 
sources of healthcare information. Given the complexity 
and scale of these datasets, it is unsurprising to observe that 
healthcare data have frequently been used in tandem with 
AI methods (Table 1). These methods can detect intricate 
patterns within complex data, improving their own perfor‑
mance through experience. For example, using claims data, 
laboratory results, and EMRs, the experiences of a large set 
of medical practitioners can be consolidated and used to 
detect patterns indicative of certain illnesses.
While these disease patterns can be used to improve the 
quality of care, this knowledge can also be used by doctors 
as a relatively unbiased complement to their decision‑mak‑
ing. AI has the potential to correct for biases due to omitted 
variables as well, using the complex patterns detected in the 
data to approximate the missing information with the infor‑
mation that is available. This has significant potential for 
use in numerous applications, such as retrospective studies 
comparing the effectiveness of different treatments.
If insurers, providers, and regulators can work together to 
increase the linkages between datasets, in a way that respects 
privacy, the capabilities driven by AI can lead to cost sav‑
ings and quality improvements throughout the healthcare 
industry.
There are risks and challenges associated with the 
increased application of AI to healthcare claims and related 
datasets (Table 1). For example, AI has had a strong influ‑
ence in the health insurance coverage process. Claim sub‑
mission, claim adjudication, and fraudulent claim detec‑
tion have either already improved or have the potential to 
improve due to the use of AI. However, the predictive abil‑
ity of AI can also be used to adjust insurance premiums in 
undesirable ways based on combinations of personal char‑
acteristics. More generally, other potential issues involve the 
confidentiality of data and appropriate use of AI tools.
These risks and challenges are not insurmountable, how‑
ever. They only imply that, as we increasingly apply more 
tools from AI, we need to be careful and responsible.
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